Asia-Pacific journal of clinical oncology最新文献

{"title":"Identification of Methionine Metabolism-Driven Heterogeneous Subtypes in Colorectal Cancer and Their Associated Immune Microenvironment.","authors":"Junhao Zhou, Wanhua Deng, Manzhao Ouyang","doi":"10.1111/ajco.70147","DOIUrl":"https://doi.org/10.1111/ajco.70147","url":null,"abstract":"<p><strong>Aim: </strong>Tumor heterogeneity, driven by metabolic reprogramming, challenges colorectal cancer (CRC) treatment. Methionine metabolism is crucial for tumor progression, but its role in CRC heterogeneity and the tumor immune microenvironment (TIME) requires systematic investigation.</p><p><strong>Methods: </strong>A systematic evaluation of 101 combinations of machine learning and statistical algorithms was conducted within a 10-fold cross-validation framework to develop and validate the optimal model, termed the methionine metabolism-related risk score (MMRS). The Cancer Genome Atlas-Colon Adenocarcinoma (TCGA-COAD) dataset served as the training cohort, while two independent Gene Expression Omnibus (GEO) cohorts (GSE39582 and GSE17536) were employed for external validation. Immune infiltration was assessed using the microenvironment cell populations-counter (MCP-counter) algorithm. Model discrimination was evaluated using time-dependent receiver operating characteristic (ROC) analysis, with the area under the curve (AUC) calculated at 1, 3, and 5 years across all cohorts.</p><p><strong>Results: </strong>Methionine metabolism-high (MMH) and metabolism-low (MML) subtypes were defined via unsupervised clustering. The MMH subtype exhibited significantly poorer overall survival and an immunosuppressive TIME. From subtype-associated differentially expressed genes (DEGs), 41 prognostic genes were identified. The optimal model (StepCox[both] + plsRcox) formed the MMRS, which effectively stratified patients into high- and low-risk groups with significantly different survival across all cohorts (all p < 0.05). Core signature genes (MID2, KIF7, GSR) were consistently selected. The high-risk group showed depleted antitumor immunity (e.g., fewer CD8+ T and NK cells) and a stroma-rich phenotype with enrichment of cancer-associated fibroblasts, underpinned by oxidative stress and alterations in energy metabolism pathways. Time-dependent ROC analysis confirmed the discriminative capacity of the MMRS, with 5-year AUCs of 0.803 (TCGA-COAD), 0.632 (GSE39582), and 0.608 (GSE17536), respectively, further supporting its prognostic accuracy across independent patient populations.</p><p><strong>Conclusion: </strong>Methionine metabolism heterogeneity is a key determinant of prognosis and immune contexture in CRC. The MMRS is a prognostic signature that effectively stratifies CRC patients by risk, though its clinical utility as a predictive biomarker for treatment selection requires prospective validation.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148598057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Two-Weekly Enfortumab Vedotin in Combination With Pembrolizumab for Advanced Urothelial Carcinoma.","authors":"Ryunosuke Nakagawa, Kouji Izumi, Kazuki Toshima, Rikushi Fujimura, Tsukasa Yoshida, Takahiro Inaba, Shuhei Aoyama, Taiki Kamijima, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Hiroaki Iwamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, Takahiro Nohara, Atsushi Mizokami","doi":"10.1111/ajco.70145","DOIUrl":"https://doi.org/10.1111/ajco.70145","url":null,"abstract":"<p><strong>Introduction: </strong>Enfortumab vedotin (EV) plus pembrolizumab (PEM) is a standard first-line therapy for advanced urothelial carcinoma (UC), but EV-related toxicities frequently lead to treatment modification or discontinuation. This study evaluated the efficacy and safety of a two-weekly EV dosing schedule combined with PEM in real-world clinical practice.</p><p><strong>Methods: </strong>This retrospective observational study included treatment-naïve patients with metastatic UC who received two-weekly EV (1.25 mg/kg) plus PEM. Treatment response, survival outcomes, adverse events (AEs), and treatment modifications were assessed.</p><p><strong>Results: </strong>Twenty patients were included. The objective response rate was 75%, including complete responses in 10% of patients. Median progression-free survival and overall survival were not reached; 6-and 12-month progression-free survival rates were 74.4% and 68.2%, respectively, and 6-and 12-month overall survival rates were 89.7% and 84.1%. Any-grade AEs occurred in 85% of patients, and grade ≥ 3 AEs occurred in 35% of patients. The most common AEs were skin reaction, peripheral sensory neuropathy, and liver dysfunction. No grade ≥ 3 cutaneous toxicities or peripheral neuropathy were observed.</p><p><strong>Conclusions: </strong>Two-weekly EV administration combined with PEM showed favorable antitumor activity with manageable toxicity in patients with advanced UC. This dose-modified regimen may represent a feasible treatment option in real-world settings, although prospective validation is warranted.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148598039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological Stress and Cancer Risk and Outcome: An Umbrella Review With Quantitative Synthesis.","authors":"Fausto Petrelli, Chiara Abeni, Emanuela Ceruti, Antonio Ghidini, Regonesi Miriam, Giordano Savelli, Alberto Zaniboni","doi":"10.1111/ajco.70144","DOIUrl":"https://doi.org/10.1111/ajco.70144","url":null,"abstract":"<p><strong>Purpose: </strong>Psychological stress, here used as an umbrella term encompassing depression, anxiety, psychosocial stress, stressful life events, perceived stress, and job strain, is hypothesized to influence cancer development and prognosis, yet epidemiologic evidence is inconsistent. This umbrella review with secondary quantitative synthesis evaluated associations between stress-related exposures and cancer incidence and mortality.</p><p><strong>Methods: </strong>PubMed was searched from inception to March 1, 2026, alongside Scopus, the Cochrane Library, citation tracking, and manual screening. Eligible studies included systematic reviews, meta-analyses, or pooled individual participant data analyses assessing depression, anxiety, psychosocial stress, stressful life events, perceived stress, or job strain in relation to cancer incidence or mortality, reporting adjusted HRs, RRs, or ORs. Random-effects models were used for secondary pooling. Overlap was assessed with corrected covered area, and evidence credibility with the Ioannidis framework.</p><p><strong>Results: </strong>Fifteen publications met inclusion criteria; eight were quantitatively synthesized, representing over four million participants. Psychological stress was not significantly associated with overall cancer incidence (pooled RR/HR 1.06; 95% CI 0.99-1.14; I² = 72.5%) or breast cancer incidence (RR/OR 1.13; 95% CI 0.95-1.34; I² = 77.8%). In contrast, cancer mortality was consistently elevated across 4 analyses (RR/HR 1.23; 95% CI 1.19-1.27; I² = 0%). Site-specific mortality risks ranged from HR 1.15 for lung cancer to HR 3.86 for leukemia. Review overlap was moderate (7.4%). Associations between depression/anxiety and cancer mortality reached Class I evidence.</p><p><strong>Conclusion: </strong>Psychological stress-related exposures were not significantly linked to cancer incidence in the available meta-analytic evidence, whereas depression, anxiety, and related distress were consistently associated with increased cancer mortality. These findings should be interpreted cautiously because residual confounding and measurement heterogeneity remain important limitations.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2026 ANZUP Annual Scientific Meeting, 28–30 June 2026. Adelaide Convention Centre, South Australia","authors":"","doi":"10.1111/ajco.70136","DOIUrl":"10.1111/ajco.70136","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 S2","pages":"S1-S107"},"PeriodicalIF":2.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70136","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benchmarking Cancer Quality Indicators by State in Australia: A Comparison of Cancer Care and Outcomes Between Queensland and Victoria.","authors":"Tracey Guan, Danny R Youlden, Tommy Hon Ting Wong, Ella Stuart, Nathan A Dunn, Nancy Tran, Helen Hunt, Danica Cossio","doi":"10.1111/ajco.70141","DOIUrl":"https://doi.org/10.1111/ajco.70141","url":null,"abstract":"<p><strong>Aims: </strong>Benchmarking quality indicators between jurisdictions provides an opportunity to identify unwarranted variations. This study compared statewide treatment and survival information for cancer between Queensland and Victoria.</p><p><strong>Methods: </strong>Population-based data were obtained separately for residents of the two states diagnosed with selected cancers between 2017 and 2021. Eleven indicators are reported involving treatments received, timeliness of treatment, and outcomes. Individual-level data were analyzed within each state to preserve governance requirements. Aggregated results were then assessed using univariate Poisson models and reported as incidence or mortality rate ratios (IRRs/MRRs) for Queensland in reference to Victoria.</p><p><strong>Results: </strong>The study cohort comprised 189,689 people. Around three-quarters (79% Queensland, 77% Victoria) received treatment. Variations in specific treatments were observed by type of cancer and state; for example, Queensland patients were more likely to receive intravenous systemic therapy for liver cancer (IRR = 1.62, 95% confidence interval [95% CI] 1.46-1.80), whereas brain cancer patients in Queensland were less likely to receive surgery compared with Victoria (IRR = 0.85, 95% CI 0.81-0.90; both p < 0.001). Treatment tended to be timelier in Victoria (overall IRR = 0.87 for Queensland, 95% CI 0.86-0.88; p < 0.001). Surgical mortality was low in both states, although brain cancer carried a higher risk. One-year survival was generally similar across both states, apart from upper gastrointestinal cancer (65% in Queensland compared to 61% in Victoria, IRR = 1.07, 95% CI 1.03-1.10; p < 0.001).</p><p><strong>Conclusion: </strong>This project demonstrates the mutual benefit of identifying areas of improvement and serves as a blueprint for other Australian states to join nationwide reporting to drive best practice in healthcare performance for people with cancer.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab","authors":"Takashi Matsuki,&nbsp;Takuro Okada,&nbsp;Chihiro Fushimi,&nbsp;Hideaki Takahashi,&nbsp;Isaku Okamoto,&nbsp;Takahito Kondo,&nbsp;Kunihiko Tokashiki,&nbsp;Kenji Hanyu,&nbsp;Takuma Kishida,&nbsp;Tatsuya Ito,&nbsp;Gai Yamashita,&nbsp;Kiyoaki Tsukahara,&nbsp;Tatsuo Masubuchi,&nbsp;Yuichiro Tada,&nbsp;Kaho Momiyama,&nbsp;Yukiko Asako,&nbsp;Kohei Hagiwara,&nbsp;Hidetaka Ikemiyagi,&nbsp;Ryohei Yaguchi,&nbsp;Nobuhiko Oridate,&nbsp;Go Omura,&nbsp;Taku Yamashita","doi":"10.1111/ajco.70012","DOIUrl":"10.1111/ajco.70012","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the correlation between hematological markers and treatment outcomes has been established. However, their predictive role in the development of immune-related adverse events (irAEs) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicenter retrospective cohort study to evaluate whether pre-treatment hematological markers—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and the CRP-albumin-lymphocyte (CALLY) index—predict the development of irAEs in 147 patients with R/M SCCHN treated with pembrolizumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Lower NLR and PLR, as well as higher LMR and CALLY index, were significantly associated with a higher incidence of irAEs. Furthermore, NLR and LMR were significantly correlated with the occurrence of severe (Grade ≥ 3) irAEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pre-treatment NLR, PLR, LMR, and CALLY index may serve as useful predictive markers for the development of irAEs in patients with R/M SCCHN treated with pembrolizumab.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"601-607"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden, Quality of Care, and Attributable Risk Factors of Young-Onset Breast Cancer (YOBC) by WHO Regions: A Systematic Analysis for the Global Burden of Disease Study 2019","authors":"Zhen Yu Wong,&nbsp;Kai Qi Ou,&nbsp;Zhen Ning Wong,&nbsp;Ryan Faderani,&nbsp;Muholan Kanapathy,&nbsp;Afshin Mosahebi","doi":"10.1111/ajco.70085","DOIUrl":"10.1111/ajco.70085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Young-onset breast cancer (YOBC) in females is often associated with aggressive features, but the current burden of YOBC remains poorly estimated. We aim to estimate the global and subregional estimate of YOBC and their attributable risk factors while evaluating the quality of care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrieved data of YOBC from the Global Burden of Disease (GBD) 1990–2019 database. Incidence, mortality, and disability-adjusted life-years (DALYs) of YOBC and attribution to each risk factor were evaluated, stratified by WHO region. Trends were estimated from 1990 to 2019. A principal component analysis was conducted to produce the quality-of-care index (QCI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>In 2019, there were 168,775 new cases of YOBC in females, 42,742 deaths driven by YOBC and 2,468,523 DALYs due to YOBC globally (2010: 89,174 cases, 29,759 deaths, and 1,692,549 DALYs). The age-standardized incidence, mortality, and DALYs rate in 2019 were 11.5 per 100,000 women, 2.9 per 100,000 women, and 168.5 per 100,000 women, respectively. The growth predominantly occurs in African and Eastern Mediterranean regions. The burden of YOBC is shifting from Europe to the Asia-Pacific region, paralleling a concurrent shift in YOBC burden attributable to smoking and alcohol consumption. Global QCI value was 77, while the African region had the lowest QCI (31).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This shift in the YOBC burden from Europe to the Asia-Pacific region mirrors the concurrent shift in burden attributable to smoking and alcohol consumption, further highlighting the necessity for targeted public health interventions in these regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"537-545"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025","authors":"Edmund Chiong,&nbsp;Renu Eapen,&nbsp;Nicholas Buchan,&nbsp;Kenneth Chen,&nbsp;Lukman Hakim,&nbsp;Agus Rizal Hamid,&nbsp;Jae-Young Joung,&nbsp;Ravindran Kanesvaran,&nbsp;Makarand Khochikar,&nbsp;Jason Letran,&nbsp;Bannakij Lojanapiwat,&nbsp;Indranil Mallick,&nbsp;Chi Fai Ng,&nbsp;Pei Ing Ngam,&nbsp;Teng Aik Ong,&nbsp;Jacob Pang,&nbsp;Darren M. C. Poon,&nbsp;Natasha Roberts,&nbsp;Marniza Saad,&nbsp;Shinichi Sakamoto,&nbsp;Jeremy Tey,&nbsp;Sue Ping Thang,&nbsp;Poh Choo Toh,&nbsp;Levent Türkeri,&nbsp;Nguyễn Tuấn Vinh,&nbsp;Alvin Wong,&nbsp;Yao Zhu,&nbsp;ANZUP Cancer Trials Group,&nbsp;Ian D. Davis","doi":"10.1111/ajco.70092","DOIUrl":"10.1111/ajco.70092","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of the fourth Asia-Pacific Advanced Prostate Cancer Symposium (APAC APCS 2025) was to discuss the application in the Asia-Pacific (APAC) region of outcomes from the fifth Advanced Prostate Cancer Consensus Conference (APCCC 2024).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The one-day symposium in September 2025 brought together 28 experts from 15 APAC countries or regions. The symposium covered five topics: (1) high-risk localized/locally advanced prostate cancer; (2) prostate-specific antigen persistence and recurrence; (3) radioligand therapy; (4) genetics and genomics; (5) bone protection and other aspects of supportive care. Presymposium polling and expert presentations prefaced in-depth discussions to gather insights on current practice and challenges in the region.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>APAC APCS 2025 highlighted the increasing complexities in diagnosis and management of advanced prostate cancer and the impact on practice of variations in access and cost. Panelists described variations in access and reimbursement for PSMA-PET/CT, abiraterone, androgen receptor pathway inhibitors, ¹⁷⁷Lu-PSMA, and bone-protecting agents. While most panelists reported access to nuclear medicine expertise, access to genetic counsellors continues to be limited in many parts of the region. Discussions highlighted creative approaches used to minimize costs while maximizing options for patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>APAC Advanced Prostate Cancer Symposia are important forums for discussing APAC-specific considerations in areas where clinical evidence is evolving. In an era of increasingly sophisticated technologies, discussions highlight the importance of not losing sight of patient and clinical factors in decision-making. Multidisciplinary and personalized management is critical, along with the need for locally relevant data to inform APAC-specific guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"546-556"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70092","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Social Media Platforms an Effective Forum for Engaging Early-Onset Cancer Survivors? Insights From X (Formerly Twitter)","authors":"Abby Dawson,&nbsp;Savio George Barreto","doi":"10.1111/ajco.70094","DOIUrl":"10.1111/ajco.70094","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Rates of early-onset pancreatic cancer (EOPC) and early-onset colorectal cancer (EOCRC) are rising globally. Although research and clinical guidelines have sought to address the psychosocial and supportive care needs of people with colorectal and pancreatic cancers, these efforts have focused largely on older adults, meaning the experiences of individuals with EOPC and EOCRC may be poorly understood. Social media offers a source of real-time, first-hand narratives that may help address this gap. This study analyzed posts on X (formerly Twitter) to explore the lived experiences and needs of people with EOPC and EOCRC to inform more age-appropriate, person-centered care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Posts containing keywords relating to EOPC and EOCRC, shared between 2023 and 2025, were extracted. Of 7441 posts retrieved, approximately 40% were categorized automatically using predefined keywords, with the remainder manually coded. Automated coding demonstrated substantial agreement with manual coding (Cohen's <i>κ</i> = 0.717).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most posts related to “academic and clinical” content (66.1%) or “medical advice and discussion” (13.5%). Only 11 posts (0.2%) described patient experiences, all relating to EOCRC, with none reflecting lived experiences of EOPC. These posts highlighted rising EOCRC incidence, late-stage diagnoses, advocacy for screening, survivorship themes, and peer support.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>X posts by people with early-onset cancers were scarce, whereas clinician- and researcher- posts dominated. This imbalance on X suggests a one-directional, paternalistic model of healthcare communication on this platform that contrasts with person-centered principles. Future research should explore alternative platforms and digital strategies to better engage younger cancer populations and support more collaborative communication.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"557-563"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70094","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study","authors":"Samantha Kurniawan,&nbsp;Angela Hwang,&nbsp;Nicole Wong Doo,&nbsp;Tracy King,&nbsp;Christian Bryant,&nbsp;Jennifer Zhang,&nbsp;Kristina Whelan,&nbsp;Parisa Fani-Molky,&nbsp;Giselle Kidson-Gerber,&nbsp;Annmarie Bosco,&nbsp;Nada Hamad,&nbsp;Gurdeep Parmar,&nbsp;Fiona Kwok,&nbsp;Sam Lai,&nbsp;Silvia Ling,&nbsp;P. Joy Ho,&nbsp;Georgia McCaughan,&nbsp;Adam Bryant","doi":"10.1111/ajco.70101","DOIUrl":"10.1111/ajco.70101","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to upfront anti-CD38 therapy within the Asia-Pacific. However, regimens proven efficacious in clinical trials utilize twice-weekly bortezomib, which is now thought to confer unacceptable toxicity, particularly in transplant-ineligible patients. There is a paucity of prospective data on RVD treatment schedules utilizing weekly bortezomib, which has implications for health care systems implementing standardized treatment based on clinical trial evidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Eighty-three patients with newly diagnosed transplant-ineligible multiple myeloma from six hospitals in Australia, received one of two RVD regimens utilizing weekly subcutaneous bortezomib (Modified SWOG and Modified RVD Lite) pragmatically adapted from their corresponding clinical trials. Baseline characteristics, response rates, toxicities, and survival were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At a median follow-up of 27.4 months, Modified SWOG achieved an ORR 91.4%, ≥ VGPR 71.4%, and 24-month progression-free survival (PFS) of 63.1% (95% CI: 47.6–83.5). Modified RVD Lite achieved an ORR 93.9%, ≥ VGPR 64.7%, and 24-month PFS of 53.6% (95% CI: 39.1–73.4). Despite dose attenuation, significant toxicity was still seen overall with hospitalizations in 48.2% and premature cessation due to toxicity in 31.3%. Peripheral sensory neuropathy was lower than in published clinical trials, reported in 32 (38.6%) patients, with Grade 3 events in only 2 patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study demonstrates that real-world outcomes of weekly RVD regimens have comparable efficacy to published twice-weekly regimens; however, toxicity remains a significant challenge in this patient population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"573-583"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70101","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}